fig3

A systematic review and network meta analysis of first-line immunotherapy for advanced urothelial carcinoma

Figure 3. Regimen comparisons within cisplatin-eligible patients. (A) Network geometry for OS; (B) Forest plot of OS HRs vs. chemotherapy with the corresponding ranks; (C) Heatmap of rank positions for OS and PFS across regimens in the cisplatin-eligible subgroup; (D) Network geometry for PFS; (E) Forest plot of PFS HRs vs. chemotherapy. OS: Overall survival; HRs: hazard ratios; PFS: progression-free survival; GC/GCb: gemcitabine plus cisplatin/gemcitabine plus carboplatin; CI: confidence interval; NA: not applicable.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/